• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Intracranial hemorrhage in immune thrombotic thrombocytopenic purpura treated with caplacizumab.

作者信息

Schofield Jeremy, Shaw Rebecca J, Lester Will, Thomas Will, Toh Cheng-Hock, Dutt Tina

机构信息

Liverpool University Hospitals NHS Foundation Trust, Liverpool, UK.

Department of Clinical Infection, Microbiology and Immunology, University of Liverpool, Liverpool, UK.

出版信息

J Thromb Haemost. 2021 Aug;19(8):1922-1925. doi: 10.1111/jth.15363. Epub 2021 Jun 9.

DOI:10.1111/jth.15363
PMID:33974343
Abstract
摘要

相似文献

1
Intracranial hemorrhage in immune thrombotic thrombocytopenic purpura treated with caplacizumab.接受卡泊单抗治疗的免疫性血栓性血小板减少性紫癜患者的颅内出血
J Thromb Haemost. 2021 Aug;19(8):1922-1925. doi: 10.1111/jth.15363. Epub 2021 Jun 9.
2
Intracranial hemorrhage in immune thrombotic thrombocytopenic purpura treated with caplacizumab: COMMENT from Eşkazan et al.用卡泊单抗治疗的免疫性血栓性血小板减少性紫癜颅内出血：埃什卡赞等人的评论
J Thromb Haemost. 2021 Oct;19(10):2644-2646. doi: 10.1111/jth.15495.
3
Caplacizumab: a change in the paradigm of thrombotic thrombocytopenic purpura treatment.卡普拉西珠单抗：血栓性血小板减少性紫癜治疗模式的改变。
Expert Opin Biol Ther. 2019 Nov;19(11):1127-1134. doi: 10.1080/14712598.2019.1650908. Epub 2019 Aug 5.
4
Von Willebrand factor assays in patients with acquired immune thrombotic thrombocytopenia purpura treated with caplacizumab.在接受卡普拉西珠单抗治疗的获得性免疫性血栓性血小板减少性紫癜患者中进行 von Willebrand 因子检测。
Br J Haematol. 2022 May;197(3):349-358. doi: 10.1111/bjh.18080. Epub 2022 Mar 8.
5
Safety and efficacy of caplacizumab retreatment in a real-life monocentric cohort of patients with immune-mediated thrombotic thrombocytopenic purpura.卡泊珠单抗再治疗在免疫性血栓性血小板减少性紫癜真实单中心队列患者中的安全性和有效性
Thromb Res. 2023 Aug;228:189-190. doi: 10.1016/j.thromres.2023.06.018. Epub 2023 Jun 16.
6
Caplacizumab: A game changer also in pregnancy-associated immune-mediated thrombotic thrombocytopenic purpura?卡普雷珠单抗：在妊娠相关免疫性血栓性血小板减少性紫癜中也是改变游戏规则的药物？
Br J Haematol. 2023 Aug;202(4):725-727. doi: 10.1111/bjh.18915. Epub 2023 Jun 8.
7
Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura.卡普雷珠单抗可降低获得性血栓性血小板减少性紫癜患者的主要血栓栓塞事件、恶化事件和死亡的发生频率。
J Thromb Haemost. 2017 Jul;15(7):1448-1452. doi: 10.1111/jth.13716. Epub 2017 Jun 5.
8
Caplacizumab to treat immune-mediated thrombotic thrombocytopenic purpura.卡泊单抗治疗免疫介导的血栓性血小板减少性紫癜。
Drugs Today (Barc). 2019 Jun;55(6):367-376. doi: 10.1358/dot.2019.55.6.2989843.
9
Real-world experience and considerations on concomitant caplacizumab and anticoagulation in thrombotic thrombocytopenic purpura.血栓性血小板减少性紫癜患者同时使用卡泊单抗和抗凝治疗的真实世界经验与考量
Ann Hematol. 2023 Feb;102(2):457-459. doi: 10.1007/s00277-022-05049-6. Epub 2022 Nov 28.
10
Caplacizumab: an anti-von Willebrand factor antibody for the treatment of thrombotic thrombocytopenic purpura.卡普芦单抗：一种抗血管性血友病因子抗体，用于治疗血栓性血小板减少性紫癜。
Am J Health Syst Pharm. 2020 Jul 23;77(15):1201-1207. doi: 10.1093/ajhp/zxaa151.

引用本文的文献

1
Tailoring caplacizumab administration using ADAMTS13 activity for immune-mediated thrombotic thrombocytopenic purpura.利用ADAMTS13活性调整卡泊单抗给药用于免疫性血栓性血小板减少性紫癜。
Blood Vessel Thromb Hemost. 2024 May 20;1(3):100010. doi: 10.1016/j.bvth.2024.100010. eCollection 2024 Sep.
2
Immune thrombotic thrombocytopenic purpura and diabetic ketoacidosis: a case report and literature review.免疫性血栓性血小板减少性紫癜与糖尿病酮症酸中毒：一例报告及文献综述
Thromb J. 2025 May 19;23(1):50. doi: 10.1186/s12959-025-00740-w.
3
Characterization of bleeding in thrombotic thrombocytopenic purpura in the precaplacizumab era: a retrospective nationwide analysis.
在普瑞凯希单抗时代血栓性血小板减少性紫癜出血情况的特征：一项全国性回顾性分析
Res Pract Thromb Haemost. 2024 Dec 12;9(1):102654. doi: 10.1016/j.rpth.2024.102654. eCollection 2025 Jan.
4
Initial US tertiary health care system experience using caplacizumab in patients with immune thrombotic thrombocytopenic purpura.美国三级医疗保健系统中使用卡普拉珠单抗治疗免疫性血栓性血小板减少性紫癜患者的初步经验。
Ann Hematol. 2024 Nov;103(11):4449-4457. doi: 10.1007/s00277-024-05993-5. Epub 2024 Sep 11.
5
Predictors of acute ischemic cerebral lesions in immune-mediated thrombotic thrombocytopenic purpura and hemolytic uremic syndrome.免疫介导性血栓性血小板减少性紫癜和溶血尿毒综合征患者急性缺血性脑病变的预测因素。
J Neurol. 2023 Oct;270(10):5023-5033. doi: 10.1007/s00415-023-11830-y. Epub 2023 Jul 1.
6
The Specificities of Thrombotic Thrombocytopenic Purpura at Extreme Ages: A Narrative Review.极端年龄下血栓性血小板减少性紫癜的特点：一项叙述性综述
J Clin Med. 2023 Apr 23;12(9):3068. doi: 10.3390/jcm12093068.
7
Caplacizumab as frontline therapy in addition to standard treatment in iTTP.卡泊单抗作为原发性血栓性血小板减少性紫癜标准治疗之外的一线治疗方法。
Blood Adv. 2023 May 23;7(10):2129-2131. doi: 10.1182/bloodadvances.2022009448.
8
Molecular Diagnosis Is Vital to the Accurate Classification and Management of Thrombotic Thrombocytopenic Purpura in Children.分子诊断对儿童血栓性血小板减少性紫癜的准确分类和管理至关重要。
Front Immunol. 2022 Apr 11;13:836960. doi: 10.3389/fimmu.2022.836960. eCollection 2022.